Company: NDRA
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001654954-25-005770
Chunk: 2

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
able  Deficit  Equity Balance as of December 31, 2023   141.397  $1   -  $-   5,937  $1  $97,583,906  $5,233  $(91,930,152) $5,658,989 Preferred stock conversion to common stock  (106.421)  (1)  -   -   4   -   1   -   -   - Common stock issued for cash  -   -   -   -   181   -   419,967   -   -   419,967 Common stock issued for warrant exercise  -   -   -   -   68   -   77,419   -   -   77,419 Fair value of vested common stock for services  -   -   -   -   46   -   80,000   -   -   80,000 Fair value of vested stock options  -   -   -   -   -   -   237,497   -   -   237,497 Stock payable toward preference dividend  -   -   -   -   -   -   4,932   (4,932)  -   - Net loss  -   -   -   -   -   -   -   -   (2,775,700)  (2,775,700)Balance as of March 31, 2024   34.976  $-   -  $-   6,236  $1  $98,403,722  $301  $(94,705,852) $3,698,172                                          

Three Months Ended March 31, 2025  Series A Convertible  Series B Convertible          Additional        Total    Preferred Stock  Preferred Stock  Common stock  Paid in    Stock   Accumulated  Stockholders’   Shares   Amount  Shares   Amount